Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
   Rule 13d-1(b)
   Rule 13d-1(c)
   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  On June 15, 2026, Sensei Biotherapeutics, Inc. changed its corporate name to Faeth Therapeutics, Inc. in connection with its acquisition of Faeth Holdings Therapeutics, Inc. and a concurrent private placement of Series B Non-Voting Convertible Preferred Stock, each completed in February 2026. Following stockholder approval on June 10, 2026, shares of Series B Non-Voting Convertible Preferred Stock automatically converted into shares of Common Stock effective June 15, 2026. The Company's Common Stock began trading on the Nasdaq Capital Market under the symbol "FTH" on June 16, 2026. The Reporting Persons previously reported beneficial ownership of 126,002 shares of Common Stock, representing 9.40% of the class, on a Schedule 13G filed with the Securities and Exchange Commission on May 15, 2026 with respect to an event date of March 31, 2026. This Amendment No. 1 is filed to report that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class.


SCHEDULE 13G




Comment for Type of Reporting Person:  On June 15, 2026, Sensei Biotherapeutics, Inc. changed its corporate name to Faeth Therapeutics, Inc. in connection with its acquisition of Faeth Holdings Therapeutics, Inc. and a concurrent private placement of Series B Non-Voting Convertible Preferred Stock, each completed in February 2026. Following stockholder approval on June 10, 2026, shares of Series B Non-Voting Convertible Preferred Stock automatically converted into shares of Common Stock effective June 15, 2026. The Company's Common Stock began trading on the Nasdaq Capital Market under the symbol "FTH" on June 16, 2026. The Reporting Persons previously reported beneficial ownership of 126,002 shares of Common Stock, representing 9.40% of the class, on a Schedule 13G filed with the Securities and Exchange Commission on May 15, 2026 with respect to an event date of March 31, 2026. This Amendment No. 1 is filed to report that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class.


SCHEDULE 13G



 
Caligan Partners LP
 
Signature:/s/ David Johnson
Name/Title:David Johnson, Managing Partner
Date:08/14/2026
 
David Johnson
 
Signature:/s/ David Johnson
Name/Title:David Johnson, Individually
Date:08/14/2026